PMC:7105881 / 46526-47744 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1513","span":{"begin":670,"end":674},"obj":"Gene"},{"id":"1514","span":{"begin":271,"end":279},"obj":"Species"},{"id":"1515","span":{"begin":593,"end":601},"obj":"Species"},{"id":"1516","span":{"begin":703,"end":711},"obj":"Species"},{"id":"1517","span":{"begin":837,"end":841},"obj":"Species"},{"id":"1518","span":{"begin":872,"end":880},"obj":"Species"},{"id":"1519","span":{"begin":1071,"end":1079},"obj":"Species"},{"id":"1520","span":{"begin":581,"end":592},"obj":"Species"},{"id":"1521","span":{"begin":936,"end":949},"obj":"Disease"}],"attributes":[{"id":"A1513","pred":"tao:has_database_id","subj":"1513","obj":"Gene:1803"},{"id":"A1514","pred":"tao:has_database_id","subj":"1514","obj":"Tax:1335626"},{"id":"A1515","pred":"tao:has_database_id","subj":"1515","obj":"Tax:1335626"},{"id":"A1516","pred":"tao:has_database_id","subj":"1516","obj":"Tax:1335626"},{"id":"A1517","pred":"tao:has_database_id","subj":"1517","obj":"Tax:10090"},{"id":"A1518","pred":"tao:has_database_id","subj":"1518","obj":"Tax:1335626"},{"id":"A1519","pred":"tao:has_database_id","subj":"1519","obj":"Tax:1335626"},{"id":"A1520","pred":"tao:has_database_id","subj":"1520","obj":"Tax:575864"},{"id":"A1521","pred":"tao:has_database_id","subj":"1521","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T279","span":{"begin":44,"end":51},"obj":"Body_part"},{"id":"T280","span":{"begin":294,"end":301},"obj":"Body_part"},{"id":"T281","span":{"begin":557,"end":564},"obj":"Body_part"},{"id":"T282","span":{"begin":604,"end":611},"obj":"Body_part"},{"id":"T283","span":{"begin":794,"end":801},"obj":"Body_part"}],"attributes":[{"id":"A279","pred":"fma_id","subj":"T279","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A280","pred":"fma_id","subj":"T280","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A281","pred":"fma_id","subj":"T281","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A282","pred":"fma_id","subj":"T282","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A283","pred":"fma_id","subj":"T283","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T248","span":{"begin":712,"end":715},"obj":"Disease"},{"id":"T250","span":{"begin":940,"end":949},"obj":"Disease"}],"attributes":[{"id":"A248","pred":"mondo_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/MONDO_0008449"},{"id":"A249","pred":"mondo_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/MONDO_0018075"},{"id":"A250","pred":"mondo_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T592","span":{"begin":148,"end":150},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T593","span":{"begin":148,"end":150},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T594","span":{"begin":471,"end":475},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"},{"id":"T595","span":{"begin":483,"end":484},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T596","span":{"begin":579,"end":580},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T597","span":{"begin":726,"end":728},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T598","span":{"begin":726,"end":728},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T599","span":{"begin":914,"end":922},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T317","span":{"begin":44,"end":51},"obj":"Chemical"},{"id":"T318","span":{"begin":148,"end":150},"obj":"Chemical"},{"id":"T319","span":{"begin":294,"end":301},"obj":"Chemical"},{"id":"T320","span":{"begin":557,"end":564},"obj":"Chemical"},{"id":"T321","span":{"begin":604,"end":611},"obj":"Chemical"},{"id":"T322","span":{"begin":726,"end":728},"obj":"Chemical"},{"id":"T323","span":{"begin":794,"end":801},"obj":"Chemical"}],"attributes":[{"id":"A317","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A318","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"},{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A321","pred":"chebi_id","subj":"T321","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A322","pred":"chebi_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"},{"id":"A323","pred":"chebi_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T98","span":{"begin":1201,"end":1217},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"2_test","denotations":[{"id":"32265848-26218507-36511189","span":{"begin":407,"end":411},"obj":"26218507"},{"id":"32265848-27050368-36511190","span":{"begin":429,"end":433},"obj":"27050368"},{"id":"32265848-26678878-36511191","span":{"begin":452,"end":456},"obj":"26678878"},{"id":"32265848-30058403-36511192","span":{"begin":471,"end":475},"obj":"30058403"},{"id":"32265848-28807998-36511193","span":{"begin":774,"end":778},"obj":"28807998"},{"id":"32265848-28807998-36511194","span":{"begin":979,"end":983},"obj":"28807998"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"LitCovid-sentences","denotations":[{"id":"T261","span":{"begin":0,"end":253},"obj":"Sentence"},{"id":"T262","span":{"begin":254,"end":565},"obj":"Sentence"},{"id":"T263","span":{"begin":566,"end":780},"obj":"Sentence"},{"id":"T264","span":{"begin":781,"end":985},"obj":"Sentence"},{"id":"T265","span":{"begin":986,"end":1218},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T736","span":{"begin":42,"end":51},"obj":"PG_1"},{"id":"T737","span":{"begin":92,"end":100},"obj":"BV_9"},{"id":"T738","span":{"begin":242,"end":252},"obj":"GO:0042571"},{"id":"T739","span":{"begin":271,"end":279},"obj":"SP_9"},{"id":"T740","span":{"begin":292,"end":301},"obj":"PG_1"},{"id":"T741","span":{"begin":370,"end":375},"obj":"NCBITaxon:10239"},{"id":"T742","span":{"begin":376,"end":383},"obj":"SO:0000440"},{"id":"T743","span":{"begin":555,"end":564},"obj":"PG_1"},{"id":"T744","span":{"begin":593,"end":601},"obj":"SP_9"},{"id":"T745","span":{"begin":602,"end":611},"obj":"PG_1"},{"id":"T746","span":{"begin":620,"end":624},"obj":"SP_9"},{"id":"T747","span":{"begin":670,"end":674},"obj":"PG_7;PR:000001341"},{"id":"T748","span":{"begin":703,"end":711},"obj":"SP_9"},{"id":"T749","span":{"begin":823,"end":833},"obj":"GO:0042571"},{"id":"T750","span":{"begin":837,"end":841},"obj":"NCBITaxon:10088"},{"id":"T751","span":{"begin":872,"end":880},"obj":"SP_9"},{"id":"T752","span":{"begin":931,"end":939},"obj":"SP_9"},{"id":"T753","span":{"begin":1071,"end":1079},"obj":"SP_9"},{"id":"T754","span":{"begin":1201,"end":1207},"obj":"UBERON:0002405;GO:0006955"},{"id":"T755","span":{"begin":1208,"end":1217},"obj":"GO:0006955"},{"id":"T19245","span":{"begin":42,"end":51},"obj":"PG_1"},{"id":"T10944","span":{"begin":92,"end":100},"obj":"BV_9"},{"id":"T3133","span":{"begin":242,"end":252},"obj":"GO:0042571"},{"id":"T39872","span":{"begin":271,"end":279},"obj":"SP_9"},{"id":"T54197","span":{"begin":292,"end":301},"obj":"PG_1"},{"id":"T63042","span":{"begin":370,"end":375},"obj":"NCBITaxon:10239"},{"id":"T96244","span":{"begin":376,"end":383},"obj":"SO:0000440"},{"id":"T65220","span":{"begin":555,"end":564},"obj":"PG_1"},{"id":"T14845","span":{"begin":593,"end":601},"obj":"SP_9"},{"id":"T56322","span":{"begin":602,"end":611},"obj":"PG_1"},{"id":"T60462","span":{"begin":620,"end":624},"obj":"SP_9"},{"id":"T79215","span":{"begin":670,"end":674},"obj":"PG_7;PR:000001341"},{"id":"T25358","span":{"begin":703,"end":711},"obj":"SP_9"},{"id":"T93063","span":{"begin":823,"end":833},"obj":"GO:0042571"},{"id":"T4667","span":{"begin":837,"end":841},"obj":"NCBITaxon:10088"},{"id":"T77387","span":{"begin":872,"end":880},"obj":"SP_9"},{"id":"T24759","span":{"begin":931,"end":939},"obj":"SP_9"},{"id":"T54709","span":{"begin":1071,"end":1079},"obj":"SP_9"},{"id":"T26753","span":{"begin":1201,"end":1207},"obj":"UBERON:0002405;GO:0006955"},{"id":"T60154","span":{"begin":1208,"end":1217},"obj":"GO:0006955"}],"text":"Subunit vaccines based on the full-length S protein cover both RBD and non-RBD neutralizing epitopes, some of which may be located in the conserved S2 subunit; thus this type of subunit vaccines are expected to induce high-titer neutralizing antibodies. Although several MERS-CoV full-length S protein-based vaccines have been reported in other vaccine types, including viral vectors and DNAs (Wang et al., 2015; Wang C. et al., 2017; Haagmans et al., 2016; Zhou et al., 2018), only a few subunit vaccines have been developed that rely on the full-length S protein. For example, a recombinant MERS-CoV S protein trimer (MERS S-2P) in prefusion conformation binds to the DPP4 receptor, as well as to the MERS-CoV NTD, RBD, and S2-specific neutralizing mAbs (Pallesen et al., 2017). Whereas this protein induces neutralizing antibodies in mice against divergent pseudotyped MERS-CoV in vitro, its in vivo protective activity against MERS-CoV infection is unknown (Pallesen et al., 2017). Therefore, more studies are needed to elucidate the potential for the development of MERS-CoV full-length S-based subunit vaccines, including understanding their protective efficacy and identifying possible harmful immune responses."}